Trial Profile
Open-Label, Uncontrolled, Multicenter Phase 2 Study of Cisplatin and 5-Fu Combined With Nimotuzumab As First-Line Treatment in Patients With Untreated Metastatic Nasopharyngeal Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2021
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Fluorouracil
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 23 Jan 2019 Results published in the Annals of Oncology
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 29 May 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov record.